WO2024205551A1 - Pharmaceutical composition for enteral detoxification and method for producing same - Google Patents

Abstract

The invention relates to medicine and pharmaceutics, and more particularly to a pharmaceutical composition for enteral detoxification. The claimed pharmaceutical composition contains, per 1 part by weight of activated charcoal, from 0.2 to 5 parts polyvinylpyrrolidone pre-dissolved in water. Also claimed is a method in which 1 part by weight of activated charcoal having a particle size of from 10 to 40 mesh is mixed with from 0.2 to 5 parts polyvinylpyrrolidone pre-dissolved in water. An active charcoal-based pharmaceutical composition for enteral detoxification which is suitable for oral administration is obtained by varying the ingredients thereof. The pharmaceutical composition suitable for oral administration has a large surface area and can be used in a large amount per therapeutic dose.

Description

PHARMACEUTICAL COMPOSITION FOR ENTERAL DETOXIFICATION AND METHOD OF ITS MANUFACTURING

The invention relates to medicine and pharmaceuticals and concerns preparations in the form of pharmaceutical compositions for enteral detoxification.

These drugs are intended for the treatment of diseases accompanied by intoxication syndrome of arbitrary etiology, in particular diseases of the gastrointestinal tract, especially those caused by pathogenic microorganisms and/or toxic substances, as well as conditions accompanied by disturbances in the normal microflora of the gastrointestinal tract.

Intoxication syndrome is a condition caused by the entry into the bloodstream of substances either not inherent to the body (exogenous toxins) or natural metabolites of the body in quantities that usually significantly exceed their normal concentrations (endogenous toxins), which have a toxic effect on the body. Depending on the type of substance and its interaction, the symptoms of intoxication may vary, but there are general symptoms characteristic of intoxication syndrome of arbitrary etiology: nausea, vomiting, diarrhea, decreased blood pressure, weakness.

Most often, intoxication syndrome develops with infectious diseases, especially of the gastrointestinal tract, for example, foodborne toxic infections (salmonellosis, escherichiosis, shigellosis - they account for about 30% of all cases), typhoid fever, cholera, gastropathogenic viruses (noroviruses, enteroviruses - they account for almost 50% of all cases), and the like.

In the practice of WHO and Western medical literature, the more comprehensive term "foodborne diseases or illnesses" is also widely used. The latter include those that arise from eating food: food poisoning, acute intestinal infections, some helminthiases, etc.

Food poisoning is divided into three groups:

- of microorganism origin (toxic infections and bacterial toxicosis - botulism, staphylococcal toxicosis);

- non-microorganism (poisoning by products containing toxic chemical compounds, such as mushrooms, mycotoxins, alkaloids of poisonous plants);

- for unknown reasons.

According to the World Health Organization, the number of food poisonings is growing annually. It is quite difficult to combine and constantly update general statistics, since only a few countries seriously deal with the calculations and systematization of food toxic infections. According to information from 5 years ago, more than 2 million people in the world die annually as a result of food poisoning. Of these, more than 75% are children under 14 years old. The approximate dynamics of the increase in the number of diseases is 10-12% annually.

The incidence of foodborne toxic infections among the population of Ukraine averages 20-40%, and in childhood even 80%.

Worldwide, 1.2 times more people die from toxic infections than from acute myocardial infarction.

Non-food poisoning - all other types of poisoning associated with the ingestion of toxic substances: for example, alcohol, methyl alcohol, chemicals, acetone, etc.

In addition, intoxication syndrome accompanies a number of chronic diseases of the body that are not associated with microorganisms, for example, liver cirrhosis, renal failure, chronic blood diseases, neoplastic processes, etc.

The toxic effects of exo- and endotoxins can manifest themselves in various ways, but help will consist in quickly binding them and removing them from the body.

Traditionally, sorbents, and in particular enterosorbents, are used to bind toxins that have entered the body (especially orally) and to reduce the manifestations of intoxication syndrome.

Interest in the use of sorbents for medical purposes increased sharply in the 1980s. This was preceded by studies by Greek scientists who showed that activated carbon can be used to effectively remove toxic products from the body by purifying the blood, which are formed in the body as a result of diseases.

Since then, a large number of sorbents have been introduced for medical purposes.

From the state of the art, an enterosorbent is known, consisting of microcrystalline cellulose (MCC) and known in Ukraine under the trade name "MCC".

Its disadvantages are: unpleasant taste, low adsorption activity, insignificant therapeutic effect, gastrointestinal discomfort tract (constipation).

Silicon dioxide powder has certain sorbent properties. A drug known under the trade name "Polysorb" is an inorganic multifunctional enterosorbent based on highly dispersed silicon dioxide.

The powder is used to prepare a suspension for oral administration. However, the use of drugs or food supplements in powder form is usually associated with greater inconvenience than the use of drugs and food supplements in other forms, especially among the pediatric category, which is most likely to suffer from intoxication syndrome associated with microorganisms.

Silicon dioxide is known to be used as a sorbent. It is used in the form of a powder, which is dissolved in water before use [RU 2236389 C1, IPC: A61K 33/00, published 10.09.1997].

But the disadvantage of this method is the need to search for water, which is inconvenient.

A pharmaceutical composition based on silicon dioxide is known in the form of a composite enterosorbent with hydrolytic lignin, microcrystalline cellulose and pectin, which contains highly dispersed silicon dioxide in the following component ratios, wt. %, in the form of a powder mixture:

Hydrolytic lignin 25.0-35.0

Microcrystalline cellulose 25.0-35.0

Highly dispersed silicon dioxide 25.0-35.0

Pectin 4.0-6.0

In addition to silicon dioxide, this enterosorbent contains hydrolytic lignin and microcrystalline cellulose, which also have adsorption capacity, as well as auxiliary substances that are used to obtain a tablet: pectin, starch, and calcium or magnesium stearate [RU 2234931 C2, IPC: A61K 35/78; A61K 33/00; A61K 47/38; A61P 1/00, published 27.08.2004, Bulletin No. 24]

But the use of such a sorbent is ineffective due to the fact that it cannot be used in large quantities for a single therapeutic dose. In addition, such a sorbent cannot be effective in intoxication of non-microorganism origin.

Also known as an enterosorbent, a product of nonlinear condensation of methylsilicic acid (in the chemical sense - polymethylsiloxane polyhydrate), known under the trade name "Enterosgel", produced in the form of a gel [Reference VIDAL. Medicines in Russia - M.: OVPEE

- Astra Pharm Service, 2000. - S.E-8].

However, such a gel has a number of significant disadvantages, namely: the impossibility of accurately dosing the required therapeutic dose, since it is used in the form of a gel and is dosed with a teaspoon and a tablespoon, the inconvenience of storing the package after the first opening, insufficiently good organoleptic properties, which in many patients cause nausea, up to vomiting, which are already symptoms of intoxication. In addition, methylsilicic acid gel, as well as silicon dioxide or lignin-based sorbents have an insignificant surface area compared to activated carbon, approximately 200-500 ^m2 /g versus 1500-2000, and sometimes 2500 ^m2 /g, which makes activated carbon the most universal and effective enterosorbent today.

Activated carbon is a universal sorbent, easy to use, as it is produced in the form of tablets, powder and is used in the chemical, food, pharmaceutical industries and in medicine. In addition, carbon is capable of exhibiting a detoxifying effect in case of poisoning with mushrooms, plant alkaloids, due to which it is widely used in medical practice [Zozulya I.S., Ivaschenko O. V. Emergency conditions in the most common poisonings. Ukrainian medical journal. - №6 (62) XI-XII 2007].

However, such a sorbent has significant disadvantages:

- the release in the form of tablets is convenient, but it does not allow you to get the required amount of sorbent in one dose - to achieve a therapeutic effect, it is necessary to use doses of 5-15 g, which corresponds to 25-75 tablets, which, naturally, is difficult for the patient.

The use of a sorbent in powder form also presents difficulties, since the coal does not wet or dissolve in water and is difficult to swallow due to the fact that the coal particles are sharp-pointed and can even cause microtrauma to the mucous membrane of the gastrointestinal tract and mouth.

Activated carbon, either in powder or tablet form, has the ability to form dust that a person can inadvertently inhale when using the carbon, which can cause bronchospasm, even an asthma attack.

Due to this fact, activated carbon is used in a limited way in children under 10 years of age. But even older children and adults can hardly swallow the required amount of carbon, usually from 5 to 15 g per dose, since it causes unpleasant sensations in the mouth, up to vomiting. Therefore, constant attempts have been made to improve the organoleptic characteristics of charcoal and improve patient compliance.

A pharmaceutical composition is known with activated carbon in the form of granules, obtained by sequentially extruding particles of activated carbon based on lignocellulose with an organic binder and subjecting the extruded granule to mechanical treatment before calcination.

This pharmaceutical composition of granulated carbon contains an organic binder which is selected from the group of natural and synthetic fibers and which contains from about 5% to about 30% by weight of binder material.

Such a pharmaceutical composition may contain an organic binder, which is selected from the group of natural resins and which consists of wood rosin, rubber rosin and tallow oil-based rosin [US 5162286 A, IPC: SOSh 31/12; VO 1J 20/20, published Nov. 10, 1992].

However, the carbon in this pharmaceutical composition has a small surface area and is therefore not used internally.

In connection with the above, there is a need to obtain new forms of adsorbents based on activated carbon, which will increase their compliance and improve the convenience of dosing.

Traditionally, the pharmaceutical industry produces tablets and/or capsules for these purposes, but this makes it impossible to take the required therapeutic dose, which is usually 50-75 times higher than that contained in the tablet.

However, in addition to coal as a sorbent that can chemically bind toxins and reduce intoxication, a preparation of polyvinylpyrrolidone with a mass of no more than 15,000 Da is used.

Polyvinylpyrrolidone is also a universal sorbent - due to free bonds it can bind with many chemical substances, forming complexes with them that are excreted from the body. For a long time it was used as part of the drug for intravenous use "hemodez" for the treatment of intoxication of any etiology. But after the fact was established that when introduced into the blood it is capable of accumulating in the reticuloendotheliocyte system and remaining there for decades, causing morphological changes in cells, polyvinylpyrrolidone was banned from intravenous use. Polyvinylpyrrolidone is used orally as an enterosorbent (since it is not absorbed from the digestive tract) under the name "Enterodez", as a means of detoxification in toxic forms of acute infectious gastrointestinal intestinal diseases (dysentery, salmonellosis, food poisoning), in liver and kidney failure [M. R. Konorev. Clinical pharmacology of new generation enterosorbents. Herald of Pharmacy. - 2O13.-№4 (62), pp. 79-85],

Like other powder sorbents, it must first be dissolved in a certain amount of water, which is a significant disadvantage for compliance.

But polyvinylpyrrolidone itself is not capable of solving the problem of detoxification of the body due to its weak binding activity, based on weak Van der Waals forces.

Therefore, attempts have always been made to combine active sorbents.

The closest to the claimed invention is a pharmaceutical composition in the form of a molded sorbent with antibacterial properties for the treatment of endometritis, which is a nanodispersed mesoporous carbon material containing polyvinylpyrrolidone with a specific adsorption surface area of no more than 50 ^m2 /g, which is made in the form of cylinders with a diameter of 2-4 mm, a length of 15-25 mm with one internal channel of a circular cross-section and is characterized by a polyvinylpyrrolidone content of at least 5.0% and a crushing strength of at least 20 kg/ ^cm2 [RU 2545743 C1, IPC: A61K 31/79; A61K 33/44; A61P 1/04; B01J 20/32; B01J 20/28; B01J 20/26; B01J 20/20; [B82B 3/00, published 10.04.2015, bulletin No. 10].

This well-known sorbent VNIITU-1-PVP ensures its easy introduction into cavities, and the presence of a channel ensures the accessibility of the external and internal surfaces for the sorption of bacterial cells. It can be mixed with water, which makes it easier to use (for example, introduction into the uterine cavity, wounds, etc.).

However, such a sorbent is used mainly externally, since the size of the particles themselves is quite large (length 40 mm and diameter 5 mm). In addition, a disadvantage is the small surface area, not exceeding 50 ^m2 /g and not allowing to sorb most chemical toxins.

A method for producing a pharmaceutical composition is known, in which pre-treated carbon is activated with phosphoric acid and granulated, which allows the particles to be given an oval shape by granulating crushed olive pits impregnated with phosphoric acid and carbonization, followed by washing and drying. The resulting granules up to 5 mm long allow for the elimination of unpleasant sensations and microtraumatization of the mucous membrane [US 5162286 A, IPC: COIB 31/12; B01J 20/20, published Nov. 10, 1992]. However, the carbon in the resulting pharmaceutical composition has a small surface area and therefore is not used internally.

A known method for producing a pharmaceutical composition in the form of a composite enterosorbent with hydrolytic lignin, microcrystalline cellulose and pectin, which contains highly dispersed silicon dioxide in component ratios, wt.%, in the form of a powder mixture by wet granulation, in which hydrolytic lignin, additionally moistened to a moisture content of 70%, is mixed sequentially with pectin, microcrystalline cellulose and highly dispersed silicon dioxide, dried to a moisture content of 5-9% and, if necessary for tabletting, powdered with a mixture of starch and magnesium or calcium stearate. [RU 2234931 C2, IPC: A61K 35/78; A61K 33/00; A61K 47/38; A61P 1/00, published 27.08.2004, Bulletin [No. 24].

This method requires appropriate technological equipment, which is quite labor-intensive, but it is especially important that the humidity of the mixture is 5%-9%, which can contribute to the development of microorganisms.

The closest to the claimed invention is a method for producing a pharmaceutical composition, which includes heat treatment of nanodispersed carbon in a hydrocarbon medium and activation with water vapor at temperatures of 700-950°C, pneumohydromechanical treatment, drying and impregnation of the sorbent with an initiator solution in N-vinylpyrrolidone, and before heat treatment, the nanodispersed carbon is mixed with a binder of 2-3.0% aqueous solution of polyethylene oxide, at a ratio of: nanodispersed carbon/binder - 1.0-1.2, extrusion of the plastic mixture, drying of the extrudate and carbonization of the binder in an inert medium at a temperature of at least 400°C are carried out [RU 2545743 C1, IPC: A61K 31/79; A61K 33/44; A61P 1/04; VO 1 J 20/32; VO 1 J 20/28; B01J 20/26;B01 J 20/20; В82В 3/00, publ. 04/10/2015, bulletin No. 10].

This method does not improve the organoleptic characteristics of coal and improve patient compliance.

The invention is based on the task of creating a pharmaceutical composition for enteral detoxification that would be convenient for oral administration - would have a large surface area and could be used in large quantities for a single therapeutic dose.

The second task, which is the basis of the invention, is the creation of a method for the production of a pharmaceutical composition for enteral detoxification, which would contribute to the improvement of the organoleptic characteristics of coal. The stated problem is solved in that the pharmaceutical composition for enteral detoxification, made on the basis of activated carbon, according to the invention, per 1 mass fraction of activated carbon includes from 0.2 to 5 parts of polyvinylpyrrolidone, previously dissolved in water.

The particle size of the activated carbon is preferably from 1Q to 40 Mesh. The mixture of carbon with an aqueous solution of polyvinylpyrrolidone may include sugar syrup in a ratio of 50-70% sugar to 50-30% water, where 1 mass fraction of carbon accounts for 0.5 to 5 mass fractions of syrup and the same amount of prepared water.

As a sugar syrup, a syrup obtained from sugar from the group of mannose, fucose, trehalose, xylose, arabinose, ribose, erythrose, maltose, lactulose can be selected, in a ratio of 50-70% sugar to 50-30% water, where for 1 mass fraction of coal there is from 0.5 to 5 mass fractions of syrup and the same amount of prepared water.

A mixture of coal with an aqueous solution of polyvinylpyrrolidone may include liquid maltitol, citric acid, sodium citrate, sodium chloride, sodium saccharin, xanthan gum, glycerin and prepared water, in the following ratio of components, %: liquid maltitol 30-60, citric acid 10-20, sodium citrate 10-20, sodium chloride 1-2, sodium saccharin 1-2, xanthan gum 1-2, glycerin 1-2, prepared water to 100.

The mixture of coal with an aqueous solution of polyvinylpyrrolidone may additionally contain prebiotics selected from the group: inulin, lactiol, beta-glucan, fructooligosaccharides, galactooligosaccharides, pectins, but not exhaustively, contain probiotics: Saccharomyces boulardii, but not exhaustively, preservatives, ethylparaben, methylparaben, domiphen bromide, benzalkonium chloride, but not exhaustively, emulsifier polysorbate 80, but not exhaustively, fragrance and taste corrector of your choice.

The second set task is solved by the fact that in the method for manufacturing a pharmaceutical composition for enteral detoxification, including the use of activated carbon, according to the invention, 1 mass fraction of activated carbon with a particle size of 10 to 40 Mesh is mixed with 0.2 to 5 parts of polyvinylpyrrolidone, previously dissolved in water. Sugar syrup can be added to the mixture of coal with an aqueous solution of polyvinylpyrrolidone with constant stirring in the range from 50 rpm to 500 rpm in a ratio of 50-70% sugar to 50-30% water, where 1 mass fraction of coal accounts for 0.5 to 5 mass parts of syrup and the same amount of prepared water until a thick, homogeneous mixture of black color is obtained.

As a sugar syrup, a syrup obtained from sugar from the group of mannose, trehalose, xylose, arabinose, ribose, erythrose, maltose, lactulose, fucose in a ratio of 50-70% sugar to 50-30% water can be selected, where for 1 mass fraction of coal there is from 0.5 to 5 mass parts of syrup and the same amount of prepared water.

To the mixture of coal with an aqueous solution of polyvinylpyrrolidone with constant stirring in the range from 50 rpm to 500 rpm, 30% to 60% liquid maltitol, 10% to 20% citric acid, 10% to 20% sodium citrate, 1% to 2% sodium chloride, 1% to 2% sodium saccharin, 1% to 2% xanthan gum, 1% to 2% glycerin and water prepared to 100% can be added.

It is the production of such a form of a pharmaceutical composition based on activated carbon, obtained according to the claimed method, that provides a sufficient therapeutic effect, which is even better than the therapeutic effect of traditional forms of carbon in powder form, but has much better organoleptic properties, is easily dosed, can be used by children, is simple to perform and is economically justified.

As the experiments show, the result, according to the invention, provides a more pronounced therapeutic effect.

Example of composition

The composition in its best form contains per 100 ml:

Activated carbon - 33.3 g

Polyvinylpyrrolidone - 33.3 g

Sugar syrup - 50 ml

Methylparaben -1.5 mg

Natamycin - 1.5 mg

Purified prepared water - up to 100 ml.

Example of the method of obtaining.

The method for obtaining a composition in the best version of execution includes the following steps:

Dissolution of 333 g of polyvinylpyrrolidone in 500 ml of water, previously heated to a temperature of 30-50°C with constant stirring.

Add 333 g of activated carbon with a particle size of 40 Mesh to 500 ml of a polyvinylpyrrolidone solution while stirring in a mixer with paddle stirrers, starting at 50 rpm, gradually increasing the stirring speed to 500 rpm until a homogeneous black mass is obtained.

Dissolve 15 mg of methylparaben and 15 mg of natamycin in 500 ml of prepared water. The solution of paraben and natamycin is added to the mixer with the previously obtained mass of syrup vugil and polyvinylpyrrolidone with constant stirring at 100 rpm for at least 10 minutes.

The resulting black homogeneous mass of syrup is poured into consumer packaging.

Examples of sorbent efficiency

Model of rotenone intoxication.

Rotenone is a complex isoflavone, colorless and odorless, which is used as an insecticide, fish poison, and broad-spectrum pesticide. In experimental medicine, it is used as a tissue respiration blocker. It occurs naturally in the seeds and stems of some plants, such as Pachyrhizus erosus and in the roots of several members of the legume family. When ingested in toxic doses by laboratory animals, it can block mitochondrial respiration, which causes tissue hypoxia and is manifested by weakness, diarrhea, lateral position of experimental animals, tremors, sometimes convulsions, and death. The LD50 orally for rats is about 60 mg/kg. The LD100 is 100 mg/kg.

Rotenone is not dangerous for humans.

The experiments were carried out on mongrel male rats weighing 200-240 g. The animals were divided into 4 groups: rotenone, coal, polyvinylpyrrolidone and coal-PVP according to the invention.

Animals of the 1st experimental group were given rotenone orally through a tube at a dose of 100 mg/kg,

Animals of the 2nd experimental group were given charcoal powder moistened with glycerin at a dose of 100 mg/kg orally through a tube 30 minutes before the administration of rotenone at a dose of 100 mg/kg.

Animals of the 3rd group were preliminarily administered an aqueous solution of PVP at a dose of 100 mg/kg orally through a tube 30 minutes before the administration of rotenone at a dose of 100 mg/kg.

Animals of the 4th group were given rotenone at a dose of 100 mg/kg 30 minutes before administration. The drug according to the invention was previously administered orally through a tube at a dose of 200 mg/kg, which corresponded to a dose of 100 mg/kg of coal and 100 mg/kg of PVP.

The time to symptom onset and the number of animals killed were assessed.

In animals of the 1st group, symptoms of poisoning in the form of motor excitation appeared at 24+/-2 minutes, and after 2 hours all animals died.

In animals of the 2nd group, symptoms of poisoning appeared at 35+/-3 minutes, after 2 hours 3 out of 6 animals died, after 24 hours 2 animals remained alive.

In animals of the 3rd group, symptoms of poisoning appeared at 30+/-5 minutes, after 2 hours 3 out of 6 animals died, after 24 hours 2 animals also remained alive.

In animals of the 4th group, symptoms of poisoning appeared at 70+/- 12 minutes, after 2 hours 1 animal out of 6 died, after 24 hours 3 animals remained alive.

Thus, it can be concluded that the preparation according to the invention has a pronounced protective effect, exceeding the effectiveness of each of the sorbents separately, and the effect of the composition is synergistic.

Model with pilocarpine administration.

Pilocarpine is a cholinomimetic used in clinical and experimental practice.

When administered orally to rats at a dose of 200 mg/kg (LD50), it causes pronounced symptoms of intoxication associated with activation of the parasympathetic nervous system: an increase in the amount of feces (diarrhea), tremors, urination, convulsions in all animals, with 50% of animals dying within 2 hours.

The same regimes of animal separation and drug administration were used as in the previous experiment.

The time to symptom onset, the number of defecations over 2 hours, and the number of animals that died during this time were assessed.

In animals of the 1st group, symptoms of poisoning in the form of tremors appeared at 14+/-2 minutes, the number of defecations was 12+/-4, 3 animals out of 6 animals died,

In animals of the 2nd group, symptoms of poisoning in the form of tremors appeared at 24+/-3 minutes, the number of defecations was 8+/-3, 1 animal out of 6 animals died.

In animals of the 3rd group, symptoms of poisoning in the form of tremors appeared at 18+/-3 minutes, the number of defecations was 11+/-2, 3 animals out of 6 animals died.

In animals of the 4th group, symptoms of poisoning in the form of tremors appeared at 28+Z-4 minutes only in 4 animals (2 animals without symptoms), the number of defecations was 6+1-2, not a single animal out of 6 animals died.

Thus, we can conclude that the drug has a pronounced protective effect. according to the invention, which exceeds the effectiveness of each of the sorbents separately and the effect of the composition is synergistic.

Industrial acceptability

All substances are available on the market, and it will not be difficult for a pharmacist to perform the appropriate calculations of the component doses and carry out the stages of manufacturing the drug according to the invention.

This pharmaceutical composition expands the list of sorbents that can be used in medical practice, especially in pediatric patients for whom activated carbon is not used.

Claims

CLAUSE OF THE INVENTION 1. A pharmaceutical composition for enteral detoxification, made on the basis of activated carbon, characterized in that per 1 mass fraction of activated carbon it includes from 0.2 to 5 parts of polyvinylpyrrolidone, previously dissolved in water. 2. The pharmaceutical composition according to claim 1, characterized in that the particle size of the activated carbon is preferably from 10 to 40 Mesh. 3. A pharmaceutical composition according to claim 1, characterized in that the mixture of coal with an aqueous solution of polyvinylpyrrolidone includes sugar syrup in a ratio of 50-70% sugar to 50-30% water, where for every 1 mass fraction of coal there is from 0.5 to 5 mass fractions of syrup and the same amount of prepared water. 4. A pharmaceutical composition according to paragraph 3, characterized in that the sugar syrup selected is a syrup obtained from sugar from the group: mannose, fucose, trehalose, xylose, arabinose, ribose, erythrose, maltose, lactulose, in a ratio of 50-70% sugar to 50-30% water, where for 1 mass fraction of carbon there is from 0.5 to 5 mass fractions of syrup and the same amount of prepared water. 5. The pharmaceutical composition according to claim 1, characterized in that the mixture of coal with an aqueous solution of polyvinylpyrrolidone includes liquid maltitol, citric acid, sodium citrate, sodium chloride, sodium saccharin, xanthan gum, glycerin and prepared water, in the following ratio of components, %: liquid maltitol 30-60, citric acid 10-20, sodium citrate 10-20, sodium chloride 1-2, sodium saccharin 1-2, xanthan gum 1-2, glycerin 1-2, prepared water to 100. 6. A pharmaceutical composition according to any of paragraphs 1-5, characterized in that the mixture of coal with an aqueous solution of polyvinylpyrrolidone additionally contains prebiotics selected from the group: inulin, lactiol, beta-glucan, fructooligosaccharides, galactooligosaccharides, pectins, but not exhaustively, contain probiotics: Saccharomyces boulardii, but not exhaustively, preservatives, ethylparaben, methylparaben, domiphen bromide, benzalkonium chloride, but not exhaustively, emulsifier polysorbate 80, but not exhaustively, fragrance and taste corrector of your choice. 7. A method for producing a pharmaceutical composition for enteral detoxification, including the use of activated carbon, characterized in that 1 mass fraction of activated carbon with a particle size of preferably 10 to 40 Mesh is mixed with 0.2 to 5 parts of polyvinylpyrrolidone, previously dissolved in water. 8. The method according to claim 7, characterized in that sugar syrup is added to the mixture of coal with an aqueous solution of polyvinylpyrrolidone with constant stirring in the range from 50 rpm to 500 rpm in a ratio of 50-70% sugar to 50-30% water, where for every 1 mass fraction of coal there is from 0.5 to 5 mass parts of syrup and the same amount of prepared water until a thick, homogeneous mixture of black color is obtained. 9. The method according to item 8, characterized in that the sugar syrup selected is a syrup obtained from sugar from the group: mannose, trehalose, xylose, arabinose, ribose, erythrose, maltose, lactulose, fucose in a ratio of 50-70% sugar to 50-30% water, where for 1 mass fraction of coal there is from 0.5 to 5 mass parts of syrup and the same amount of prepared water. 10. The method according to claim 7, characterized in that 30% to 60% liquid maltitol, 10% to 20% citric acid, 10% to 20% sodium citrate, 1% to 2% sodium chloride, 1% to 2% sodium saccharin, 1% to 2% xanthan gum, 1% to 2% glycerin and water prepared to 100% are added to the mixture of coal with an aqueous solution of polyvinylpyrrolidone with constant stirring in the range from 50 rpm to 500 rpm.